Form D · Biotechnology
Merlin Biotech, Inc.
Doylestown, PA · CIK 0002149714
Offering snapshot reported Aug 11, 2026 · SEC filing
- Reported sold
- $50K Offering amount: $50K
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 30, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 11, 2026 | Initial | $50,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-593781
Source: Form D, filed Aug 11, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jay Bhatia | Director |
| Carol Brosgart | Director |
| Loren Danzis | Director |
| Nikhil Heble | Executive |
| Randall Hyer | Director, Executive |
| Nick Spring | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3805 Old Easton Road
Doylestown, PA, 18901
Phone: 215-589-6111
Doylestown, PA, 18901
Phone: 215-589-6111